Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets ...

Antibody-drug conjugates (ADCs) link cancer drug payloads, such as tubulin inhibitors and DNA damaging agents, to monoclonal antibodies that selectively target tumor cells. Pernille Hemmingsen, PhD, ...

Amivantamab is a bispecific antibody targeting epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor, demonstrating efficacy in patients with non–small cell lung cancer ...

Coherus Oncology (CHRS) announced the publication of preclinical and clinical biomarker research in Molecular Cancer Therapeutics describing the ...

In blood cancers such as chronic lymphocytic leukemia, B cells of the immune system multiply uncontrollably. One form of therapy involves labeling the CD20 protein on the surface of the B cells with ...

An ambitious project led by Vanderbilt University Medical Center investigators aims to use artificial intelligence technologies to generate antibody therapies against any antigen target of interest.

INCA033989 targets CALR mutations, showing efficacy in engineered cell lines and mouse models of MPNs, without affecting other cells. CALR mutations are significant in JAK2V617F-negative essential ...

French biotech Innate Pharma is recruiting natural-born killers to target B cell non-Hodgkin lymphoma (B-NHL). The company’s tetraspecific antibody controlled tumors and improved survival in mice and ...

A new approach targets the B-cell pathway with bispecific antibodies, building on decades of research that establishes the role of B cells and self-reactive antibodies in lupus, systemic sclerosis, ...